Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Gene Revolution: Transforming Lives through Gene Editing Therapeutics

This image opens in the lightbox

News provided by

BCC Research LLC

20 Nov, 2024, 16:34 GMT

Share this article

Share toX

Share this article

Share toX

"The Gene Editing Therapeutics Market is all about developing advanced treatments that can directly change genes to treat or cure diseases. It's like fixing the root cause of a health issue at the DNA level, offering hope for conditions that were once thought to be untreatable. This market is rapidly growing as these innovative therapies become more widely researched and used."

BOSTON, Nov. 20, 2024 /PRNewswire/ -- "According to the latest study from BCC Research, the demand for Gene Editing Therapeutics is estimated at $11 million in 2024 and is forecast to grow at a CAGR of 147% to reach $1.0 billion by the end of 2029.

This report takes a close look at the current and future possibilities of gene editing treatments and explores the factors that will help or hinder their use. It also examines the competitive landscape, including what therapeutics companies are working on and how they plan to bring new treatments to market. Additionally, it predicts how the market will evolve by 2029 and provides in-depth profiles of key players, including their business focus, financials, and products.

Interesting Facts about the Gene Editing Therapeutics Market

  • The gene editing therapeutics market is just getting started, with the first approved treatment, Casgevy, coming to market in the U.K. and U.S. at the end of 2023. This groundbreaking treatment, developed by CRISPR Therapeutics and Vertex, uses CRISPR/Cas9 technology to edit genes.

  • Casgevy's reach is expected to increase as it is set to become available for children between the ages of 5-12.

  • While most new treatments are still in early development, two promising ones are close to a 2029 market launch: NTLA-2001 and cema-cel.

  • There are challenges. Gene therapies are expensive and difficult to manufacture. To address this, some companies are outsourcing production and some are trying to secure government reimbursement for these life-changing treatments for rare diseases.

To obtain more insights and information about the gene editing therapeutics market, click here.

Factors contributing to this market's growth include:

  1. Increasing Prevalence of Chronic Diseases. More and more people are living with long-term health conditions, such as heart disease, diabetes and cancer. This trend is partly due to the world's aging population. In addition, these diseases often require ongoing treatment.

  2. Increasing Prevalence of Rare Genetic Disorders. More people are being diagnosed with uncommon, inherited health conditions caused by changes in their genes. As medical knowledge and genetic testing improve, researchers will become better at identifying these rare disorders, leading to more cases being recognized and treated.

  3. Precision Medicine.: This is a tailored approach to healthcare that focuses on treating individuals based on their unique genetic makeup, lifestyle, and environment. Instead of a one-size-fits-all method. Precision medicine provides the most effective treatment for each person, ensuring better outcomes by considering what makes each patient unique.

Request a Sample Copy of the Gene Editing Therapeutics Market

Report Synopsis

Report Metrics

Details

Base year considered

2023

Forecast period considered

2024-2029

Market size forecast

$1.0 billion

Growth rate

CAGR of 147.0% for the forecast period of 2024-2029

Regions covered

North America, Europe and Emerging Markets

Market drivers

•  Increasing prevalence of chronic diseases and rare genetic disorders

•  Precision medicine

This report addresses the following questions:

  1. What are the projections for the market?
    The gene editing therapeutics market is estimated at $11 million in 2024 and is forecast to grow at a CAGR of 147% to reach $1.0 billion by the end of 2029.

  2. What factors are driving the growth of the market?
    - Increasing prevalence of chronic diseases and rare genetic disorders.
    - Need for precision medicine

  3. What segments are covered in the market?
    Because only one product has been approved to date, with other products still under development, the market is segmented only by region.

  4. Which region has the highest market share?
    North America holds the highest share in the market and will continue to do so through the forecast period.

Market leaders include:

  • Allogene Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences Inc.
  • Crispr Therapeutics
  • Editas Medicine
  • Intellia Therapeutics Inc.
  • Precision Biosciences
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Verve Therapeutics Inc.
  • Vor Bio

More related reports:

Global Market for Cell and Gene Therapy: The worldwide industry that develops and sells treatments that use cells or genes to repair or replace damaged or diseased cells can be thought of like a repair shop for the body, where cells or genes are used to fix or replace faulty ones, helping to cure diseases and improve health. This market includes companies working on these innovative treatments.

Directly Purchase a copy of the report from BCC Research.

For further information or to make a purchase, please get in touch with info@bccresearch.com.

About BCC Research
BCC Research market reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype. 

Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: info@bccresearch.com,
Phone: +1 781-489-7301

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library. 

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. 

Logo - https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

Modal title

Also from this source

BCC Research Presents 2024 Diagnostics Research Review: Market Growth and Innovations

BCC Research Presents 2024 Diagnostics Research Review: Market Growth and Innovations

BCC Research announces the release of its "2024 Diagnostics Research Review," shining a spotlight on the significant growth of and advances in the...

Global Market for Emerging Medical Device Technologies to Hit $223.9 Billion by 2029

Global Market for Emerging Medical Device Technologies to Hit $223.9 Billion by 2029

According to the latest study from BCC Research, the "Global Markets for Emerging Medical Device Technologies" is expected to increase from $136.6...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.